BridgeBio Pharma
Yahoo Finance • 22 days ago
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F as... Full story
Yahoo Finance • last month
PayPal downgraded, Roku upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Roku (ROKU) to Buy... Full story
Yahoo Finance • last month
Here Are Thursday’s Top Wall Street Analyst Research Calls: American Eagle Outfitters, Ferrari, Intuitive Surgical, Roku, PayPal, Synopsis, Visa, and More
Chaay_Tee / iStock via Getty Images Quick Read As expected, the Federal Reserve cut the Funds rate 25 basis points on Wednesday. The rate cut lowered the Fed funds rate to 3.50%-3.75%, the lowest since the post-pandemic era in 2022. Rate... Full story
Yahoo Finance • 2 months ago
BridgeBio to Participate in December Investor Conferences
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its managemen... Full story
Yahoo Finance • 2 months ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on November 17, 2025, th... Full story
Yahoo Finance • 2 months ago
Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?
24/7 Wall St. Quick Read Alphabet (GOOG,GOOGL) holds a portfolio of 37 stocks worth $2.5B to $3B through its venture arms GV and CapitalG. Google’s portfolio is heavily tilted toward healthcare and biotech with its largest holding being... Full story
Yahoo Finance • 2 months ago
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to pla... Full story
Yahoo Finance • 2 months ago
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital po... Full story
Yahoo Finance • 2 months ago
Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.
Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments... Full story
Yahoo Finance • 2 months ago
BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue
Earnings Call Insights: BridgeBio Pharma (BBIO) Q3 2025 MANAGEMENT VIEW * Neil Kumar, CEO, opened the call highlighting "continued momentum, both scientifically and commercially in this franchise and are ever more confident today that... Full story
Yahoo Finance • 2 months ago
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
- $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue - As of October 25, 2025, 5,259 unique... Full story
Yahoo Finance • 2 months ago
Here are the major earnings after the close Wednesday
Major earnings expected after the bell on Wednesday include: * Microsoft Corporation (MSFT [https://seekingalpha.com/symbol/MSFT]) * Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) * Meta Platforms (META [https://seekingalpha... Full story
Yahoo Finance • 3 months ago
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline resu... Full story
Yahoo Finance • 3 months ago
BridgeBio rises after late-stage muscular dystrophy trial success
[Double exposure microscope Young woman scientific using equipment for research. Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21/iStock via Getty Images BridgeBio Pharma (NASDAQ:BBIO... Full story
Yahoo Finance • 3 months ago
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, glycosylated αDG, si... Full story
Yahoo Finance • 3 months ago
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its managemen... Full story
Yahoo Finance • 3 months ago
SA Asks: What's the most attractive biotech stock right now?
[Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21 What's the most attractive biotech stock right now for investors? Seeking Alpha analysts ONeil Trader [https://seekingalpha.com/autho... Full story
Yahoo Finance • 3 months ago
BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds. Analysts at Piper Sandler have reaffirmed their ‘Overweight’ rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with an unchanged... Full story
Yahoo Finance • 4 months ago
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reductio... Full story
Yahoo Finance • 4 months ago
Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock?
PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant vola... Full story
